Home About Us Categories Latest Reports News Room Contact us

NA Whole Exome Sequencing Market - Industry Trends and Forecast to 2029

Report Code: 81660

Industry: Medical Devices & Consumables

Published On: 2022/07/22

Pages: 175

Publisher : Data Bridge Market Research

North America whole exome sequencing (WES) Market is projected to register a substantial CAGR of 22.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Whole Exome Sequencing (WES) Market, By Component (Second generation sequencing and Third-Generation sequencing), Product and Service (systems, kits and services), Application (Drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others ), End User (pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others), Distribution Channel (direct trade, retail sales and others), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the North America whole exome sequencing (WES) market are:

• Increase in the adoption of whole exome sequencing (WES)
• Growing usage of targeted sequencing methods
Market Segmentation:
North America Whole Exome Sequencing (WES) market is categorized into four notable segment which is Component, Product and Service, Application, End User and Distribution Channel.

• On the basis of component, the global whole exome sequencing (WES) market is segmented into second generation sequencing and third-generation sequencing.

• On the basis of Product and Service, the global whole exome sequencing (WES) market is segmented into systems, kits and services.


• On the basis of Application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

• On the basis of End user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.

• On the basis of Distribution Channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.


Market Players:

The key market players for North America whole exome sequencing (WES) market are listed below:

• CD Genomics
• Twist Bioscience
• PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
• GeneDx, LLC
• Psomagen

Market Definition:

Whole Exome Sequencing (WES) is NGS (nest generation sequencing) technology used for strategically sequencing the coding region of the genome that is the exon. The exome, which is the total of all exons of an organism, represents only 1–2% of the total genome and is actually converted into proteins after translation. It is responsible for the occurrence of nearly 85% of genetic diseases. Whole exome sequencing is widely used for identifying and determining genetic variants responsible for various diseases such as Miller Syndrome and Alzheimer’s disease among others.
Adoption of whole exome sequencing technology by new consumers ad increase in use of whole exome sequencing technology for scientific applications are accelerating the market demand.
Market Segmentation:
North America whole exome sequencing market is categorized into five notable segments which are based on component, product and service, application, end user and distribution channel. In 2022, second generation sequencing segment is expected to dominate the market due to technological advancement in the whole exome sequencing.
• On the basis of component, the whole exome sequencing market is segmented into second generation sequencing and third-generation sequencing.
• On the basis of product and service, the whole exome sequencing market is segmented into systems, kits and services.
• On the basis of application, the whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
• On the basis of end user, the whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
• On the basis of distribution channel, the whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 PRODUCT TYPE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
4.1 PORTER’S FIVE FORCES 58
4.2 PESTEL ANALYSIS 59
4.3 INDUSTRIAL INSIGHTS: 60
4.4 CONCLUSION 61
5 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS 62
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 66
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 66
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 66
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 67

6.2 RESTRAINTS 68
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 68
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 68
6.3 OPPORTUNITIES 69
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 69
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 69
6.4 CHALLENGES 70
6.4.1 LACK OF SKILLED PROFESSIONALS 70
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 70
7 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 71
7.1 OVERVIEW 72
7.2 SECOND-GENERATION SEQUENCING 75
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 76
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 76
7.3 THIRD-GENERATION SEQUENCING 77
8 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 78
8.1 OVERVIEW 79
8.2 SYSTEMS 82
8.2.1 HISEQ SERIES 83
8.2.1.1 HISEQ 2500 83
8.2.1.2 HISEQ 1500 83
8.2.2 MISEQ SERIES 83
8.2.3 ION TORRENT PLATFORMS 84
8.2.3.1 ION PROTON 84
8.2.3.2 ION PGM 84
8.2.4 OTHERS 84
8.3 KITS 84
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 85
8.3.2 LIBRARY PREPARATION KITS 85
8.3.3 TARGET ENRICHMENT KITS 86
8.3.4 OTHERS 86
8.4 SERVICES 86
8.4.1 SEQUENCING SERVICES 87
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 87
8.4.3 OTHERS 87

9 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 DRUG DISCOVERY AND DEVELOPMENT 92
9.3 AGRICULTURE & ANIMAL RESEARCH 93
9.4 DIAGNOSTICS 93
9.5 PERSONALIZED MEDICINE 94
9.6 OTHERS 95
10 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY END USER 96
10.1 OVERVIEW 97
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
10.3 ACADEMIC & RESEARCH INSTITUTES 101
10.4 HOSPITALS AND CLINICS 101
10.5 CLINICAL LABORATORIES 102
10.6 OTHERS 103
11 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 104
11.1 OVERVIEW 105
11.2 DIRECT TRADE 108
11.3 RETAIL SALES 108
11.4 OTHERS 110
12 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY REGION 111
12.1 NORTH AMERICA 112
12.1.1 U.S. 120
12.1.2 CANADA 123
12.1.3 MEXICO 126
13 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 129
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 129
14 COMPANY PROFILE 130
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 130
14.1.1 COMPANY SNAPSHOT 130
14.1.2 REVENUE ANALYSIS 130
14.1.3 COM PANY SHARE ANALYSIS 131
14.1.4 PRODUCT PORTFOLIO 131
14.1.5 RECENT DEVELOPMENTS 131

14.2 MERCK KGAA 133
14.2.1 COMPANY SNAPSHOT 133
14.2.2 REVENUE ANALYSIS 133
14.2.3 COM PANY SHARE ANALYSIS 134
14.2.4 PRODUCT PORTFOLIO 134
14.2.5 RECENT DEVELOPMENTS 134
14.3 EXODX (A PART OF BIO-TECHNE) 135
14.3.1 COMPANY SNAPSHOT 135
14.3.2 REVENUE ANALYSIS 135
14.3.3 COM PANY SHARE ANALYSIS 136
14.3.4 PRODUCT PORTFOLIO 136
14.3.5 RECENT DEVELOPMENTS 136
14.4 THERMO FISHER SCIENTIFIC INC. 137
14.4.1 COMPANY SNAPSHOT 137
14.4.2 REVENUE ANALYSIS 137
14.4.3 COM PANY SHARE ANALYSIS 138
14.4.4 PRODUCT PORTFOLIO 138
14.4.5 RECENT DEVELOPMENTS 138
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 139
14.5.1 COMPANY SNAPSHOT 139
14.5.2 REVENUE ANALYSIS 139
14.5.3 COM PANY SHARE ANALYSIS 140
14.5.4 PRODUCT PORTFOLIO 140
14.5.5 RECENT DEVELOPMENTS 140
14.6 AZENTA US, INC. 142
14.6.1 COMPANY SNAPSHOT 142
14.6.2 PRODUCT PORTFOLIO 142
14.6.3 RECENT DEVELOPMENTS 142
14.7 BECKMAN COULTER, INC 144
14.7.1 COMPANY SNAPSHOT 144
14.7.2 REVENUE ANALYSIS 144
14.7.3 PRODUCT PORTFOLIO 145
14.7.4 RECENT DEVELOPMENTS 145
14.8 BIONEER CORPORATION 146
14.8.1 COMPANY SNAPSHOT 146
14.8.2 REVENUE ANALYSIS 146
14.8.3 PRODUCT PORTFOLIO 147
14.8.4 RECENT DEVELOPMENTS 147

14.9 CD GENOMICS 148
14.9.1 COMPANY SNAPSHOT 148
14.9.2 PRODUCT PORTFOLIO 148
14.9.3 RECENT DEVELOPMENTS 148
14.10 CEGAT GMBH 149
14.10.1 COMPANY SNAPSHOT 149
14.10.2 PRODUCT PORTFOLIO 149
14.10.3 RECENT DEVELOPMENTS 149
14.11 EUROFINS SCIENTIFIC 150
14.11.1 COMPANY SNAPSHOT 150
14.11.2 REVENUE ANALYSIS 150
14.11.3 PRODUCT PORTFOLIO 151
14.11.4 RECENT DEVELOPMENTS 151
14.12 GENEDX, LLC 152
14.12.1 COMPANY SNAPSHOT 152
14.12.2 PRODUCT PORTFOLIO 152
14.12.3 RECENT DEVELOPMENTS 152
14.13 GENEFIRST LIMITED. 154
14.13.1 COMPANY SNAPSHOT 154
14.13.2 PRODUCT PORTFOLIO 154
14.13.3 RECENT DEVELOPMENTS 154
14.14 ILLUMINA, INC 156
14.14.1 COMPANY SNAPSHOT 156
14.14.2 REVENUE ANALYSIS 156
14.14.3 PRODUCT PORTFOLIO 157
14.14.4 RECENT DEVELOPMENTS 157
14.15 INTEGRATED DNA TECHNOLOGIES, INC. 159
14.15.1 COMPANY SNAPSHOT 159
14.15.2 PRODUCT PORTFOLIO 159
14.15.3 RECENT DEVELOPMENTS 159
14.16 MERIDIAN BIOSCIENCE, INC. 161
14.16.1 COMPANY SNAPSHOT 161
14.16.2 REVENUE ANALYSIS 161
14.16.3 PRODUCT PORTFOLIO 162
14.16.4 RECENT DEVELOPMENTS 162
14.17 PSOMAGEN 163
14.17.1 COMPANY SNAPSHOT 163
14.17.2 REVENUE ANALYSIS 163
14.17.3 PRODUCT PORTFOLIO 163
14.17.4 RECENT DEVELOPMENTS 164
14.18 QIAGEN 165
14.18.1 COMPANY SNAPSHOT 165
14.18.2 REVENUE ANALYSIS 165
14.18.3 PRODUCT PORTFOLIO 166
14.18.4 RECENT DEVELOPMENTS 166
14.19 SOPHIA GENETICS 167
14.19.1 COMPANY SNAPSHOT 167
14.19.2 REVENUE ANALYSIS 167
14.19.3 PRODUCT PORTFOLIO 168
14.19.4 RECENT DEVELOPMENTS 168
14.20 TWIST BIOSCIENCE 169
14.20.1 COMPANY SNAPSHOT 169
14.20.2 REVENUE ANALYSIS 169
14.20.3 PRODUCT PORTFOLIO 170
14.20.4 RECENT DEVELOPMENTS 170
15 QUESTIONNAIRE 172
16 RELATED REPORTS 175